Methods of treatment using a gastric retained gabapentin dosage

Details Methods of treatment using a gastric retained gabapentin dosage Methods of treatment using a gastric retained gabapentin dosage

2002-10-25

2008-10-21

Sheikh, Humera N (Department: 1618)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S464000, C424S472000, C424S489000

Reexamination Certificate

active

07438927

ABSTRACT:
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4152326 (1979-05-01), Hartenstein et al.
patent: 4894476 (1990-01-01), Butler et al.
patent: 4996058 (1991-02-01), Sinnreich et al.
patent: 5007790 (1991-04-01), Shell
patent: 5084479 (1992-01-01), Woodruff
patent: 5582837 (1996-12-01), Shell
patent: 5872984 (1999-02-01), Berglund et al.
patent: 5906832 (1999-05-01), Jao et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6054482 (2000-04-01), Augart et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6162466 (2000-12-01), Licht et al.
patent: 6255526 (2001-07-01), Pesachovich et al.
patent: 6294690 (2001-09-01), Deering et al.
patent: 6310098 (2001-10-01), Guttuso, Jr.
patent: 6333352 (2001-12-01), Derakhshan
patent: 6340475 (2002-01-01), Shell et al.
patent: 6451808 (2002-09-01), Cowles
patent: 6488962 (2002-12-01), Berner et al.
patent: 6635281 (2003-10-01), Wong et al.
patent: 2001/0043946 (2001-11-01), Vilkov
patent: 2002/0012679 (2002-01-01), Bruna et al.
patent: 2003/0031711 (2003-02-01), Fara et al.
patent: 2003/0100611 (2003-05-01), Berner et al.
patent: 2003/0104053 (2003-06-01), Gusler et al.
patent: 2005/0064036 (2005-03-01), Berner et al.
patent: 2006/0159743 (2006-07-01), Berner et al.
patent: 0 458 751 (1991-05-01), None
patent: 1 118 321 (2001-07-01), None
patent: WO 01/13894 (2001-03-01), None
patent: WO 01/97612 (2001-12-01), None
patent: WO 01/97782 (2001-12-01), None
patent: WO 03/002151 (2003-01-01), None
Davis et al., “Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy,” Br. J. Clin. Pharmac. (1988) 26:435-443.
Fix, “Oral drug delivery, small intestine and colon,” in Controlled Drug Delivery, Mathiowitz, ed., Wiley & Sons, Inc., 1999, pp. 699-700.
Grundy and Foster, “The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties,” Clin. Pharmacokinet. (1988) 26:435-443.
Rocci et al., “Food-induced gastric retention and absorption of sustained -release procainamide,” Clin. Pharmacol. Ther. (1987) 42:45-49.
Stevenson et al., “Colonic absorption of antiepileptic agents,” Epilepsia (1997) 38:63-67.
Welling and Barbhaiya, “Influence of food and fluid volume on chlorothiazide bioavailability: comparison of plasma and urinary excretion methods,” J. Pharm. Sci. (1982) 71:32-35.
Wilding et al., “Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of15N-labelled drug to healthy volunteers,” Br. J. Clin. Pharmac. (1991) 32:573-579.
Bennett et al. (2004) “Gabapentin in the treatment of neurophathic pain”Palliative Med., 18(1):5-11.
Richter et al. (Nov. 2005) “Pregabalin or morphine and gabapentin for neuropathic pain”Expert Op. on Pharmacotherapy, 6(14):2535-2539.
Wesche et al. (Mar. 2005) “A pharmacokinetic comparison of pregabalin and gabapentin”J. of Pain, 6(3), abstract only.
NDA 20-235 (U.S. Food and Drug Administration application No. 020235).
NDA 20-882 (U.S. Food and Drug Administration application No. 020882).
NDA 21-129 (U.S. Food and Drug Administration application No. 021129).
Laird et al. (Jun. 2000) “Use of gabapentin in the treatment of neuropathic pain”Ann. Pharmacotherapy, 34:802-807.
Goa et al. (1993) “Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy”Drugs46(3):409-427.
Wheeler, G. (2002) “Gabapentin”Curr. Op. Invest. Drugs, 3(3):470-477.
Benetello et al. (1997) “Oral gabapentin disposition in patients with epilepsy after a high-protein meal”Epilepsia, 38(10):1140-1142.
Piyapolrungroj et al. (2001) “Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine”Pharm. Res.18(8):1126-1130.
Bennett et al. (Aug. 2000) “Future directions in the management of pain by intraspinal drug delivery”J. Pain and Symptom Management, 20(2):S44-S50.
Stevenson et al. (Aug. 1997) “Contrasting nutrient effects on the plasma level of an amino acid-like antiepileptic agent from jejunal administration in dogs”J. Pharm. Sci.86(8):953-957.
Solaro et al. (2000) “Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis”Multiple Sclerosis, 6:192-193.
U.S. Appl. No. 09/425,491, Shell John W. et al.
U.S. Appl. No. 10/029,134, Berner et al.
U.S. Appl. No. 10/014,750, Berner et al.
U.S. Appl. No. 10/045,816, Berner et al.
U.S. Appl. No. 10/024,932, Berner et al.
U.S. Appl. No. 10/066,146, Lim et al.
U.S. Appl. No. 10/045,823, Shell et al.
U.S. Appl. No. 10/213,823, Berner et al.
U.S. Appl. No. 10/235,076, Markey et al.
U.S. Appl. No. 10/281,284, Berner et al.
U.S. Appl. No. 10/293,217, Berner et al.
Andrews et al., “Gabapentin: a New Agent for the Management of Epilepsy,”Annals of Pharmacotherapy28:1188-1196 (1994).
Asconapé et al., “Myoclonus Associated with the Use of Gabapentin,”Epilepsia: 41(4):479-481 (2000).
Backonja et al., “Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus,”JAMA280(21): 1831-1836 (1998).
Bebin et al., “New Anticonvulsant Drugs: Focus on Flunarizine, Fosphenytoin, Midazolam, and Stiripentol,”Drugs48(2): 153-171 (1994).
Benedetti, “Enzyme Induction and Inhibition by New Antiepileptic Drugs: a Review of Human Studies,”Fundam. Clin. Pharmacol.14: 301-319 (2000).
Ben-Menachem, “New Antiepileptic Drugs and Non-pharmacological Treatments,”Current Opinion in Neurology, 13: 165-170 (2000).
Bennett et al., “Future Directions in the Management of Pain by Intraspinal Drug Delivery,”Journal of Pain and Symptom Management20(2): S44-250 (Aug. 2000).
Bernus et al., “Anticonvulsant Therapy in Aged Patients: Clinical Pharmacokinetic Considerations,”Drugs&Aging10(4): 278-289 (1997).
Beydoun, “Monotherapy Trials of New Antiepileptic Drugs,”Epilepsia38 (Suppl. 9): S21-S31 (1997).
Bialer, “Comparative Pharmacokinetics of the Newer Antiepileptic Drugs,”Clinical Pharmacokinetics24(6): 441-452 (1993).
Blum et al., “Pharmacokinetics of Gabapentin in Subject with Various Degrees of Renal Function,”Clinical Pharmacology and Therapeutics56(2): 154-159 (1994).
Bourgeois, “New Antiepileptic Drugs,”Arch Neurol.55: 1181-1183 (1998).
Bourgeois, “Important Pharmacokinetic Properties of Antiepileptic Drugs,”Epilepsia36(Suppl. 5): S1-S7 (1995).
Bourgeois, “Pharmacokinetic Properties of Current Antiepileptic Drugs: What Improvements are Needed?”Neurology55 (Suppl 3): S11-S16 (2000).
Boyd et al., “Clinical Research: Effects of Age and Gender on Single-Dose Pharmacokinetics of Gabapentin,”Epilepsia40(4): 474-479 (1999).
Brown et al., “Cloning and Deletion Mutagenesis of the α2δ Calcium Channel Subunit from Porcine Cerebral Cortex,”Journal of Biological Chemistry273(39): 25458-25465 (1998).
Browne, “Long-Term Efficacy and Toxicity of Gabapentin,”Neurology43: A307 (1993) (578P).
Chadwick, “Gabapentin,”Lancet343(Jan. 8): 89-91 (1994).
Chadwick, “An Overview of the Efficacy and Tolerability of New Antiepileptic Drugs,”Epilepsia38 (Suppl. 1): S59-S62 (1997).
Chadwick et al., “Clinical Administration of New Antiepileptic Drugs: An Overview of Safety and Efficacy,”Epilepsia37 (Suppl. 6): S17-S22 (1996).
Cramer et al., “New Antiep

Affiliated with

Also associated with

Rating

Methods of treatment using a gastric retained gabapentin dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using a gastric retained gabapentin dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using a gastric retained gabapentin dosage will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4000653